

## **Impression to Supply Mandibular Advancement Devices for Sleep Apnoea to all 180 Sleep Clinics Owned by Air Liquide Healthcare Australia**

### **Highlights:**

- Impression will supply the Sleep Guardian ‘Silensor’ and ‘Dorsal’ mandibular advancement devices to Air Liquide Healthcare Australia (‘ALH’)
- ALH will supply the devices to its network of patients from 180 sleep clinics Australia-wide
- Historically, ALH performs over 12,000 sleep assessments per annum with about 50% of all sleep assessments resulting in recommendation for a mandibular advancement device
- IHL has exclusivity of supply over all devices for which impressions are taken within the ALH sleep clinics
- Impression and ALH will conduct joint marketing and promotional campaigns, which will include the use of ALH’s extensive existing client database.

Impression Healthcare Limited (‘Impression’, ‘IHL’ or the ‘Company’), developer of four unique medicinal cannabis products, owner of INCANNEX™ cannabis oils and oral devices manufacturer, is pleased to announce that it has entered a product supply agreement with Air Liquide Healthcare Pty Ltd (‘ALH’ or ‘Air Liquide Healthcare Australia’) for an initial period of 5 years.

Impression will supply the Sleep Guardian ‘Silensor’ and ‘Dorsal’ mandibular advancement devices to ALH who in turn will supply the devices to its network of patients from 180 sleep clinics operated throughout Australia. Patients can either take their own teeth impressions within the sleep clinic for the Silensor or have a dentist take the patient’s impression for the Dorsal product. Importantly, Impression has exclusivity over all devices for which impressions are taken within the ALH sleep clinics. To complete the supply process, IHL will manufacture the oral devices based on the impressions provided by ALH and have the finished product delivered to the patient.

ALH historically conducts approximately 12,000 sleep assessments per annum with about 50% of all sleep assessments resulting in the formal patient recommendation for a mandibular advancement device.

**Managing Director and CEO of Impression healthcare, Mr Joel Latham said;** “We’re delighted to enter such an impactful partnership with Air Liquide Healthcare Australia to further grow the partnerships and revenue potential of our oral devices division.

This agreement demonstrates our commitment to ameliorating sleep apnoea and ALH is the perfect partner for us due to its extensive collective experience and networks related to the treatment of sleep apnoea in Australia, and we are now a strong part of ALH’s product mix.”

The two parties to the agreement will also conduct joint marketing and promotional campaigns, which will include the use of ALH’s extensive existing client database.



Date: 27th August 2019  
ASX Announcement (ASX: IHL)

#### **About Air Liquide Healthcare Pty Ltd**

Air Liquide Healthcare has over 20 years of experience in providing medical products and services for the alleviation of Sleep Apnoea and other breathing disorders. Its staff are committed to providing patients with high-quality support, focused on education, assessment, therapy initiation and on-going support. The Company is a subsidiary of Air Liquide S.A., a French multinational company listed on the Euronext and a component company of the CAC40.

**ENDS**

#### **About Impression Healthcare Limited (ASX: IHL)**

Impression Healthcare Limited (IHL.ASX) is undertaking four clinical trials investigating the use of uniquely formulated medicinal cannabis products for the treatment of Obstructive Sleep Apnoea, Traumatic Brain Injury/Concussion, Periodontitis (Gum Disease) and Temporomandibular Joint Disorder. Each indication represents major global markets.

IHL has its Australian licenses in place to import, export and distribute cannabis products and has launched a line of EU GMP-approved CBD oil products under the brand, "Incannex™". Incannex™ oils may be sold under IHL's product supply and distribution agreement with Cannvalate Pty Ltd – the largest network of cannabis medicine prescribers in Australia.

Impression also has a collaboration and "first right of refusal" agreement with leading US Cannabinoid therapeutics Company, AXIM Biotechnologies Incorporated and a license agreement with Resolution Chemicals for the production and distribution of Dronabinol in the USA, Canada, Australia and New Zealand.

Providing growing revenues to the Company; Impression continues to build its customised oral devices manufacturing business both direct-to-the-consumer and via the Company's growing B2B preferred practitioner network.

**Investors:** [investors@impression.healthcare](mailto:investors@impression.healthcare)

**Website:** [www.impression.healthcare](http://www.impression.healthcare)